ReviewOncoTargets and therapy2026
The Robotic Interval Surgery, A Game-Changer in Optimal Debulking for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Review in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study evaluates the role of robotic-interval debulking surgery (robotic IDS) compared to traditional laparotomy as the game-changer in surgical outcome and complications for ovarian cancer patients. Patients and Methods: Following PRISMA guidelines, relevant literature published between 2014 and 2024 was retrieved from PubMed, Scopus, Google Scholar, EBSCOHost, and SAGE Journals. Out of 816 studies, four were included, assessed for bias using ROBINS-I and analyzed with random-effects meta-analysis with RevMan 5.4. Results: A total of four studies involving 166 patients were analyzed. The findings indicate that robotic IDS has a significant result on achieving complete cytoreduction (OR of 6.67 [p = 0.0003]), reducing estimated blood loss (SMD of -0.71 [p = 0.02]), and shorter hospital stay (SMD of -1.58 [p<0.00001]). The result also shows promising effects on intraoperative complications with an OR of 0.82 [p=0.86] and postoperative complications with an OR of 0.40 [p=0.11]. Conversely, there is a longer operative time in robotic IDS compared to laparotomy with a SMD of 0.40 [p = 0.26]. Conclusion: Robotic IDS advances surgical management of advanced-stage (stage III-IV) and recurrent ovarian cancer, offering improved cytoreduction rates, reduced blood loss, and shorter hospital stays. A promising effect was also observed on intraoperative and postoperative complications, although operative time was longer. Further research is needed to demonstrate clearer clinical advantages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.